New combo therapy aims to tame bone marrow cancer
NCT ID NCT06773195
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether adding ulixertinib to the standard drug ruxolitinib is safe and helpful for people with myelofibrosis, a type of bone marrow cancer. About 37 adults who are already on a stable dose of ruxolitinib will receive different doses of ulixertinib. The goal is to find the best dose with few side effects and see if the combination improves symptoms.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ruxolitinib and ulixertinib
What this could lead to
If successful, this could point toward a new combination treatment that better controls myelofibrosis symptoms and progression.
What could go wrong
This is an early phase 1/2 trial with only 37 participants, so safety and effectiveness are not yet proven. Side effects from the drug combination may occur.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELOFIBROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cleveland Clinic
NOT_YET_RECRUITINGCleveland, Ohio, 44195, United States
Contact Phone: •••-•••-••••
-
Massachusetts General Hospital (Data Collection Only)
RECRUITINGBoston, Massachusetts, 02114, United States
Contact Phone: •••-•••-••••
-
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)
RECRUITINGBasking Ridge, New Jersey, 07920, United States
Contact Phone: •••-•••-••••
-
Memorial Sloan Kettering Bergen (Limited Protocol Activities)
RECRUITINGMontvale, New Jersey, 07645, United States
Contact Phone: •••-•••-••••
-
Memorial Sloan Kettering Cancer Center
RECRUITINGNew York, New York, 10065, United States
Contact Phone: •••-•••-••••
-
Memorial Sloan Kettering Monmouth (Limited Protocol Activities)
RECRUITINGMiddletown, New Jersey, 07748, United States
Contact Phone: •••-•••-••••
-
Memorial Sloan Kettering Nassau (Limited Protocol Activities)
RECRUITINGUniondale, New York, 11553, United States
Contact Phone: •••-•••-••••
-
Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities)
RECRUITINGCommack, New York, 11725, United States
Contact Phone: •••-•••-••••
-
Memorial Sloan Kettering Westchester (Limited Protocol Activities)
RECRUITINGHarrison, New York, 10604, United States
Contact Phone: •••-•••-••••